Roberto Adamo obtained his PhD in Pharmaceutical Science from the University of Catania (Italy) in 2003, with a thesis on the synthesis of biologically relevant inositols. He two post-doctoral fellowships at the NIH in Bethesda (USA), under the supervision of Dr. P. Kovac, and in the group of Prof. J. P. Kamerling at the Utrecht University (The Netherlands). In 2007 he joined Novartis Vaccines under the supervision of Dr. Paolo Costantino where he was later appointed Head of the Carbohydrate Chemistry Laboratory, and Leader of the Conjugation & Synthesis Platform. Following the company acquisition by GSK he became Preclinical Representative Leader of the Conjugation Platform in 2016 and Conjugation Platform Leader in 2018. Currently he is also Project Leader in the AMR area. His research interests focus on the synthesis of glycans, glycoconjugates and glyconanoparticles to be used for carbohydrate-based therapeutics. He is authors of about 80 papers and book chapters and 12 patents.